Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab (BI 655066) in Moderate to Severe Chronic Plaque Psoriasis
NCT02054481Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2014
- Primary completion
- Nov 2014
- Countries
- 7
01
Overview
A Phase 2 trial of risankizumab in psoriasis, sponsored by Boehringer Ingelheim. Started Feb 2014; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02054481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054481.